[Cell therapies in cardiology: results from the first randomized clinical trials].
Following acute myocardial infarction, necrotic cardiac tissue is replaced by scar leading to ventricular remodeling and pump failure. Transplantation of autologous bone marrow-derived cells into the heart, early post-infarct, aims to prevent ventricular remodeling. This strategy has been evaluated in four controlled, randomized clinical trials, which provided mixed results. A transient improvement in ventricular function was observed in one trial, and a modest improvement (the duration of which remains to be determined) in an additional trial, whereas two trials showed negative results. A modest benefit of bone marrow cell transplantation was also observed in patients with chronic ischemic heart disease. Despite mixed results reported so far, cell therapy of heart disease still is in its infancy and has considerable room for improvement.
Vassalli
G
G
Service de cardiologie, CHUV, Lausanne. giuseppe.vassalli@chuv.ch
Gersbach
P
P
Ferrari
E
E
Tozzi
P
P
Ruchat
P
P
Delay
D
D
Hurni
M
M
Moccetti
T
T
von Segesser
L K
LK
Vogt
P
P
D016026:Bone Marrow Transplantation; D006801:Humans; D009203:Myocardial Infarction / Q000601:surgery*; D016032:Randomized Controlled Trials as Topic